Trump's Stock Picks Perfectly Timed With New Medicare Rules: Report - Eli Lilly (NYSE:LLY)
Federal disclosures show seven Lilly purchases on Trump’s behalf as Medicare and FDA actions advanced the company’s obesity-drug business.
- On May 14, ethics disclosures revealed President Donald Trump purchased up to $680,000 in Eli Lilly stock between January and March, coinciding with administration initiatives that benefited the drugmaker's GLP-1 business.
- The Centers for Medicare & Medicaid Services proposed a pilot program, a temporary "bridge," allowing Medicare patients to pay $50 a month for GLP-1 drugs to expand access to obesity treatments.
- FDA Commissioner Marty Makary approved the weight loss pill Foundayo in 50 days, while the agency intensified a crackdown on "compounded" GLP-1s, which critics charge are often unsafe alternatives to Lilly's branded products.
- Eric Trump, a Trump Organization executive, stated that individual stock trades occur without family discretion, though legal ethicist Kathleen Clark warned such actions undermine public trust in government motives and potential personal enrichment.
- Lilly expects 2026 revenue to exceed $80 billion, as analysts anticipate a favorable market impact from Medicare coverage of obesity medications by July 1, 2026, positioning the firm to capitalize on expanded government reimbursement.
11 Articles
11 Articles
Trump Bought Eli Lilly Stock As His Administration Moved To Qualify Obesity Drug For Medicare Coverage
KFF Health News reports: President Donald Trump earlier this year bought as much as $680,000 in stock of Eli Lilly, the maker of blockbuster obesity drugs, as the agencies he oversees undertook an agenda that largely benefited the company. On May 14, the federal government released ethics disclosures revealing a list of stock and bond trades made on Trump’s behalf from January to March of this year. They included extensive trades across the econ…
Follow the money: Trump stock purchases align perfectly with favors to drugmaker
President Donald Trump earlier this year bought as much as $680,000 in stock of Eli Lilly, the maker of blockbuster obesity drugs, as the agencies he oversees undertook an agenda that largely benefited the company.On May 14, the federal government released ethics disclosures revealing a list of stock and bond trades made on Trump’s behalf from January to March of this year. They included extensive trades across the economy, including investments…
kffhealthnews.org
Trump Bought Stock in Drugmaker as His Government Boosted Its Obesity Drugs
President Donald Trump earlier this year bought as much as $680,000 in stock of Eli Lilly, the maker of blockbuster obesity drugs, as the agencies he oversees undertook an agenda that largely benefited the company. On May 14, the federal government released ethics disclosures revealing a list of stock and bond trades made on Trump’s behalf from January to March of this year. They included extensive trades across the economy, including investment…
Trump has bought shares in Eli LillyCorrected May 18 at 8:58 p.m. – see correction at the bottom. Earlier this year, US President Donald Trump bought shares in Novo competitor Eli Lilly for up to 680.0
Coverage Details
Bias Distribution
- 57% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
